ClinicalTrials.gg
Not yet recruitingNCT07214623iCURE cSDHUpdated Oct 9, 2025

Prospective Multi-center Single Arm Study for Subjects With Chronic Subdural Hematoma Treated With i-ED COILs, Either Alone or in Combination With Burr-holes or Mini-craniotomy

An observational study in Chronic Subdural Hematoma, cSDH and Chronic Subdural Hematomas, sponsored by Kaneka Medical America LLC. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Kaneka Medical America LLC (part of Kaneka Corporation) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.

Started
2025
with 3 others
Observational
7 of 22
5 open now
Registered
16th of 22
by date
Lead sponsor
1 of 22
Kaneka Medical America LLC

Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one is one of 4 that started in 2025, is one of 7 observational ones, and was the 16th registered.

Hematoma, Subdural, Chronic

113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.

Browse Hematoma, Subdural, Chronic studies →

Open to participants now

10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hematoma, Subdural, Chronic with a site in United States, or all of them as a file.
02

Study summary

All participants will be asked to have a minimally invasive procedure for the treatment of chronic subdural hematoma, a blood clot on the brain. Depending on the specific condition patients may also have a surgical procedure, a mini-craniotomy or burr holes where the skull is pierced and the blood clot is drained.

03

Conditions studied

  • Chronic Subdural Hematoma
  • cSDH
  • Chronic Subdural Hematomas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic subdural hematomas with symptoms

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre morbid mRS 0-3
  • Chronic subdural symptomatic, requiring intervention

Exclusion criteria

Exclusion Criteria:

  • Acute subdural hematoma
  • Intercranial mass other than subdural hematoma
  • Females pregnant or breast feeding
  • Compromised survival or inability to complete trial
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Interventions

  • DeviceNeuro endovascular embolic coil

    i-ED COIL, Kaneka Corporation

    Also known as: Embolization coil

06

What researchers measure

Primary outcomes

  1. Effectiveness

    Incidence of hematoma recurrence or progression requiring repeat embolization within 180 days

    Time frame: 6 months

  2. Safety

    Modified rankin scale at 90 days post procedure

    Time frame: 90 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Nov 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 9, 2025
StartEst.
Nov 30, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
May 31, 2027
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07214623
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Nov 30, 2025 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Oct 9, 2025

Study contacts

Yuki Arimoto
Contact
yuki.arimoto@kaneka.com
212-705-4340
Leah Lyons, PA
Contact
leah.lyons@kaneka.com
212-705-4340
Fawaz Al-Mufti, MD
principal investigator · Westchester Medical Center
Jan-Karl Burkhardt, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion